FDA also placed Global Pharma Healthcare Private Limited on import alert for providing an inadequate response to a records request and for not complying with CGMP requirements. The import alert ...

Halol is one of Sun Pharma's export-oriented manufacturing units and was ... The company had earlier stated that the import alert will have no impact on its specialty revenue and it would evaluate ...

The FDA also reiterated its previous warning against the ... The US drug regulator previously issued an import alert on Global Pharma’s plant in January which means they are not allowed to manufacture ...

The company’s Halol plant, receiving an import alert from the USFDA earlier in December ... Ex-milestone, the specialty sales were up 21.6% YoY in Q3FY23. Sun Pharma Q3 Results: Profit rises 5% YoY to ...

The import alert prevents these products from entering the U.S., according to the FDA. NewsNation reached out to Global Pharma for comment. “Using contaminated artificial tears increases the risk of ...

Sun Pharma's acquisition of Concert adds a complementary ... trials and is expected by the company to be filed with the US FDA in 1HCY23. “Given the unmet medical need and a strong efficacy ...

Brokerage firm Jefferies has termed Sun Pharmaceuticals as its top pick in the Indian pharma sector, while maintaining its Buy call on the back of the company’s specialty strategy and its strong India ...

Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma's Global Dermatology Portfolio MUMBAI, India and PRINCETON ...

Sun Pharmaceutical ... by the US FDA. Pre-tax NPV of Rs 64 per share for Deuruxolitinib Sun’s competitive positioning is expected to be strong. Jefferies expects Sun Pharma to leverage its ...

Lupin, Sun Pharma share price: Wild swings in the Indian share market come in the backdrop of sharp falls in the global markets owing to weakness in the banking space, after the collapse of US-based ...